MX356269B - Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña. - Google Patents
Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña.Info
- Publication number
- MX356269B MX356269B MX2013013533A MX2013013533A MX356269B MX 356269 B MX356269 B MX 356269B MX 2013013533 A MX2013013533 A MX 2013013533A MX 2013013533 A MX2013013533 A MX 2013013533A MX 356269 B MX356269 B MX 356269B
- Authority
- MX
- Mexico
- Prior art keywords
- cgrp
- photophobia
- antibodies
- fragments
- subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
Abstract
La presente invención se refiere a usos de un anticuerpo relacionado con el gen dela calcitonina (CGRP) o fragmento del anticuerpo para inhibir la fotofobia asociada a CGRP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161488660P | 2011-05-20 | 2011-05-20 | |
US201161496860P | 2011-06-14 | 2011-06-14 | |
PCT/US2012/038875 WO2012162257A2 (en) | 2011-05-20 | 2012-05-21 | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013013533A MX2013013533A (es) | 2014-09-04 |
MX356269B true MX356269B (es) | 2018-05-21 |
Family
ID=47175058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013533A MX356269B (es) | 2011-05-20 | 2012-05-21 | Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña. |
Country Status (16)
Country | Link |
---|---|
US (3) | US9708393B2 (es) |
EP (2) | EP2709663B1 (es) |
JP (4) | JP6374789B2 (es) |
KR (2) | KR101965461B1 (es) |
CN (3) | CN108014334B (es) |
AU (3) | AU2012258980B8 (es) |
BR (1) | BR112013029959A8 (es) |
CA (2) | CA2836800A1 (es) |
CY (1) | CY2022019I2 (es) |
DK (1) | DK2709663T3 (es) |
EA (1) | EA034747B1 (es) |
IL (1) | IL229434B (es) |
MX (1) | MX356269B (es) |
NZ (1) | NZ732970A (es) |
SG (1) | SG194973A1 (es) |
WO (1) | WO2012162257A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2433251T5 (es) | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos |
RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
AU2012258980B8 (en) * | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
US9855332B2 (en) | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
TWI646111B (zh) | 2011-05-20 | 2019-01-01 | 艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途 |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
MX2016012188A (es) | 2014-03-21 | 2017-04-27 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
UY36302A (es) * | 2014-09-15 | 2016-04-29 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas |
CA2980162C (en) | 2015-03-26 | 2024-06-18 | Jacqueline M. Iversen | Methods and compositions to inhibit symptoms associated with veisalgia |
KR102648281B1 (ko) | 2015-04-16 | 2024-03-14 | 하. 룬드벡 아크티에셀스카브 | 항-pacap 항체 및 그의 용도 |
JOP20200116A1 (ar) * | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
TWI770020B (zh) | 2016-04-15 | 2022-07-11 | 丹麥商H朗德貝克公司 | 人類化抗pacap 抗體及其用途 |
KR20190066607A (ko) * | 2016-09-23 | 2019-06-13 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
WO2018055573A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
WO2018160897A1 (en) | 2017-03-02 | 2018-09-07 | Beth Israel Deaconess Medical Center, Inc. | Preventing post-ictal headaches |
MA52202A (fr) | 2018-04-02 | 2021-02-17 | Amgen Inc | Compositions d'érénumab et utilisations de celles-ci |
US20220023389A1 (en) * | 2018-12-10 | 2022-01-27 | University Of Copenhagen | Vasodilators for use in the treatment of a retinal ischemic disorder |
CN109528670B (zh) * | 2018-12-28 | 2021-05-07 | 正大制药(青岛)有限公司 | 一种琥珀酸夫罗曲坦片及其制备方法 |
JOP20210166A1 (ar) * | 2019-01-08 | 2023-01-30 | H Lundbeck As | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r |
JP2022516956A (ja) * | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療 |
CN110151184A (zh) * | 2019-04-19 | 2019-08-23 | 昆明依利科特科技有限公司 | 非接触式吸毒人员快速检测系统及方法 |
JOP20210247A1 (ar) * | 2019-05-02 | 2023-01-30 | H Lundbeck As | علاج الصداع باستخدام أجسام مضادة لـ cgrp |
WO2020239014A1 (zh) * | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | 抗cgrp抗体及其应用 |
KR20210124867A (ko) * | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
IT202000029459A1 (it) * | 2020-12-03 | 2022-06-03 | Alberto Chiarugi | Terapia dei disturbi emotivi |
RU2763476C1 (ru) * | 2021-01-13 | 2021-12-29 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) | Способ лечения мигрени |
IL310885A (en) | 2021-08-27 | 2024-04-01 | H Lundbeck As | Treatment of cluster headache using anti-CGRP antibodies |
CN114632156B (zh) * | 2022-05-17 | 2022-08-16 | 中国人民解放军军事科学院军事医学研究院 | Tim-3在预防、治疗或减轻疼痛中的应用 |
WO2024032750A1 (zh) * | 2022-08-11 | 2024-02-15 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3662333A (en) | 1970-09-08 | 1972-05-09 | Bendix Corp | Hydraulic accumulator charge detector and indicating system |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU570600B2 (en) | 1983-06-15 | 1988-03-17 | Celltech Limited | Peptides, pharmaceutical compositions,genes,vectors,host organisms, processes for there production and diagnostic reagents |
JPS62129297A (ja) | 1985-08-09 | 1987-06-11 | Toyo Jozo Co Ltd | カルシトニン遺伝子関連ペプチド誘導体 |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5364841A (en) | 1988-01-11 | 1994-11-15 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
JPH10504457A (ja) | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | カルシトニンレセプター |
FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
JPH11512396A (ja) | 1995-09-05 | 1999-10-26 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
WO1998009630A1 (en) | 1996-09-09 | 1998-03-12 | Smithkline Beecham Corporation | Compounds and methods |
JP3483893B2 (ja) | 1996-09-10 | 2004-01-06 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
WO1998056779A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
CA2345357A1 (en) | 1998-09-30 | 2000-04-06 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
US20010036647A1 (en) | 1998-10-22 | 2001-11-01 | Prabhakara V. Choudary | Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
AU2001240020B9 (en) | 2000-03-01 | 2008-12-04 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
US20020162125A1 (en) | 2001-03-06 | 2002-10-31 | Anne-Marie Salmon | Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal |
US20030181462A1 (en) | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
CN1617737A (zh) | 2001-11-26 | 2005-05-18 | 普罗特米克斯公司 | 用于使哺乳动物组织中的脂质水平正常化的组合物和方法 |
ES2327830T3 (es) | 2002-03-29 | 2009-11-04 | Schering Corporation | Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen. |
US7879991B2 (en) | 2002-05-06 | 2011-02-01 | Noxxon Pharma Ag | CGRP binding nucleic acids |
US20040110170A1 (en) | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
AU2003237255B8 (en) | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
DK1556020T3 (da) | 2002-08-12 | 2009-06-22 | Birkir Sveinsson | Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
WO2004050683A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
EP1575517B1 (en) | 2002-12-24 | 2012-04-11 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
CA2519515A1 (en) | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
US7192954B2 (en) | 2003-03-14 | 2007-03-20 | Merck & Co., Inc. | Monocyclic anilide spirohydantoin CGRP receptor antagonists |
CA2519475A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
EP1605936B1 (en) | 2003-03-14 | 2011-07-20 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin cgrp receptor antagonists |
JP4690313B2 (ja) | 2003-03-14 | 2011-06-01 | メルク・シャープ・エンド・ドーム・コーポレイション | カルボキサミドスピロヒダントインcgrp受容体アンタゴニスト |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
ATE466860T1 (de) | 2003-04-15 | 2010-05-15 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
WO2004097421A2 (en) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
AU2004259675A1 (en) | 2003-07-15 | 2005-02-03 | Merck & Co., Inc. | Hydroxypyridine CGRP receptor antagonists |
DK2330201T3 (en) | 2003-10-22 | 2017-07-24 | Keck Graduate Inst | PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY |
US20080070239A1 (en) | 2003-10-29 | 2008-03-20 | University Of Rochester | Detection of neureopeptides associated with pelvic pain disorders and uses thereof |
JP2007517911A (ja) | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ, インコーポレイテッド | 心臓血管の適応症および腎臓の適応症に対してcgrpを使用する方法 |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TWI432196B (zh) | 2005-01-18 | 2014-04-01 | Euro Celtique Sa | 內臟痛的治療 |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
WO2007025212A2 (en) | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
ES2433251T5 (es) | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos |
US20070108378A1 (en) | 2005-11-14 | 2007-05-17 | Toru Terabayashi | High pressure optical cell for a downhole optical fluid analyzer |
US8071770B2 (en) | 2005-11-18 | 2011-12-06 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl CGRP receptor antagonists |
WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
US9074352B2 (en) | 2006-03-27 | 2015-07-07 | John R. Ramun | Universal control scheme for mobile hydraulic equipment and method for achieving the same |
NZ572807A (en) | 2006-05-19 | 2011-10-28 | Alder Biopharmaceuticals Inc | Culture method for obtaining a clonal population of antigen-specific b cells |
PE20080153A1 (es) | 2006-06-08 | 2008-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) |
ATE469895T1 (de) | 2006-07-21 | 2010-06-15 | Vertex Pharma | Cgrp-rezeptorantagonisten |
MX2009012492A (es) | 2007-05-21 | 2010-01-20 | Alder Biopharmaceuticals Inc | Anticuerpos para il-6 y sus usos. |
US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
TWI609965B (zh) | 2007-05-21 | 2018-01-01 | 艾爾德生物控股有限責任公司 | 新穎兔抗體人化方法以及經人化之兔抗體 |
BRPI0908276B8 (pt) | 2008-03-04 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite |
RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
KR101519192B1 (ko) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법 |
AR081434A1 (es) | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
AU2012258980B8 (en) * | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
US9855332B2 (en) * | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
TWI646111B (zh) * | 2011-05-20 | 2019-01-01 | 艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途 |
JP2017051288A (ja) * | 2015-09-07 | 2017-03-16 | キューカンパニー株式会社 | ゴルフ用具 |
MX2018003713A (es) | 2015-09-24 | 2018-08-15 | Teva Pharmaceuticals Int Gmbh | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). |
JP2022516956A (ja) | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療 |
JOP20210166A1 (ar) | 2019-01-08 | 2023-01-30 | H Lundbeck As | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r |
-
2012
- 2012-05-21 AU AU2012258980A patent/AU2012258980B8/en active Active
- 2012-05-21 CN CN201711101237.9A patent/CN108014334B/zh active Active
- 2012-05-21 EA EA201301293A patent/EA034747B1/ru active IP Right Revival
- 2012-05-21 KR KR1020137033855A patent/KR101965461B1/ko active IP Right Grant
- 2012-05-21 DK DK12790022.3T patent/DK2709663T3/da active
- 2012-05-21 CA CA2836800A patent/CA2836800A1/en active Pending
- 2012-05-21 SG SG2013084579A patent/SG194973A1/en unknown
- 2012-05-21 US US13/476,632 patent/US9708393B2/en active Active
- 2012-05-21 EP EP12790022.3A patent/EP2709663B1/en active Active
- 2012-05-21 KR KR1020197008921A patent/KR102098546B1/ko active IP Right Grant
- 2012-05-21 EP EP18208809.6A patent/EP3508501A1/en active Pending
- 2012-05-21 CN CN201711101258.0A patent/CN107827982B/zh active Active
- 2012-05-21 NZ NZ732970A patent/NZ732970A/en unknown
- 2012-05-21 CA CA3048709A patent/CA3048709A1/en active Pending
- 2012-05-21 CN CN201280035852.3A patent/CN103702685B/zh active Active
- 2012-05-21 JP JP2014512931A patent/JP6374789B2/ja active Active
- 2012-05-21 BR BR112013029959A patent/BR112013029959A8/pt not_active Application Discontinuation
- 2012-05-21 MX MX2013013533A patent/MX356269B/es active IP Right Grant
- 2012-05-21 WO PCT/US2012/038875 patent/WO2012162257A2/en active Application Filing
-
2013
- 2013-11-14 IL IL229434A patent/IL229434B/en active IP Right Grant
-
2017
- 2017-03-16 JP JP2017051288A patent/JP6695295B2/ja active Active
- 2017-06-13 US US15/621,105 patent/US10266587B2/en active Active
- 2017-08-22 AU AU2017218971A patent/AU2017218971B2/en active Active
-
2018
- 2018-05-15 JP JP2018093614A patent/JP6701262B2/ja active Active
-
2019
- 2019-02-25 JP JP2019031652A patent/JP6754456B2/ja active Active
- 2019-04-18 US US16/388,184 patent/US11325967B2/en active Active
- 2019-06-14 AU AU2019204209A patent/AU2019204209B2/en active Active
-
2022
- 2022-06-20 CY CY2022019C patent/CY2022019I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX356269B (es) | Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña. | |
MX2022006568A (es) | Agentes anti-cd20, agentes anti-cd22, y usos y combinaciones de los mismos con una celula que expresa un receptor de antigeno quimerico (car) de cd19. | |
EA201592042A1 (ru) | Композиции антител против cgrp и их применение | |
MX2017013267A (es) | Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). | |
MX2020012816A (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. | |
MX361242B (es) | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. | |
MX2017001864A (es) | Tratamientos conjuntos con anticuerpos anti cd40. | |
PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
MX2019006835A (es) | Uso de anticuerpos anti-cgrp o anti-cgrp-r o fragmentos de anticuerpo para tratar o prevenir formas cronicas y agudas de diarrea. | |
MX2020009260A (es) | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos. | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
WO2014004549A3 (en) | Anti-mesothelin binding proteins | |
EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
SG10201807042YA (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
NZ630881A (en) | Use of semaphorin-4d binding molecules for treatment of atherosclerosis | |
BR112014008804A2 (pt) | suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos | |
MX2018012939A (es) | Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas. | |
CL2020002468A1 (es) | Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018) | |
PH12020551323A1 (en) | Anti cd6 antibodies for treating severe asthma | |
MX2015004389A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods. | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
NZ702178A (en) | Lingo-2 antagonists for treatment of conditions involving motor neurons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |